Tesamorelin

Tesamorelin is a synthetic analogue of full-length growth hormone releasing hormone (GHRH 1-44) with a trans-3-hexenoic acid modification at the N-terminal tyrosine residue. This lipophilic N-terminal cap protects the Tyr1-Glu2 bond from DPP-IV cleavage — the primary inactivation route for native GHRH — while preserving the complete authentic 44 amino acid GHRH sequence. This distinguishes Tesamorelin from truncated analogues (CJC-1295 variants using 29 residues) and makes it the full-length GHRH reference compound in pharmacological research.

Molecular formula: C223H370N72O69 | Molecular weight: 5135.91 g/mol | CAS: 901758-09-6 | Parent peptide: GHRH(1-44) | Amino acids: 44 | N-terminal modification: trans-3-hexenoic acid | Purity: greater than or equal to 98% as verified by HPLC | Form: Lyophilised powder | Appearance: White to off-white lyophilised powder | Storage: -20°C desiccated

Tesamorelin activates GHRHR — a class B GPCR on pituitary somatotroph cells — via Gs/cAMP/PKA signalling to stimulate GH gene transcription and secretory granule exocytosis. Its plasma half-life of approximately 30 minutes produces pulsatile GH release similar to CJC-1295 (No DAC) but from the complete GHRH sequence, enabling comparative pharmacology studies examining the contribution of GHRH C-terminal residues (positions 30-44) to receptor activation kinetics. Falutz et al. (NEJM, 2007) published the key clinical pharmacology data.

Complements IGF-1 LR3 research (stimulating upstream GH production versus direct IGF-1R activation), Ipamorelin research (complementary GHS-R1a/GHRHR dual-receptor paradigms), and CJC-1295 comparative pharmacology.

Supplied as a lyophilised powder. Reconstitute with bacteriostatic water. Store at -20°C. For laboratory and analytical research purposes only. Not for human or veterinary use.